HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

N.J. Lawmakers To Consider Age Restriction For DXM

This article was originally published in The Tan Sheet

Executive Summary

The state legislature’s Law and Public Safety Committee in November unanimously passed the bill to require photo identification for purchases of products containing dextromethorphan and impose a fine of up to $750 on employees and retail establishments for violations.

You may also be interested in...



Cough Drug Abuse By Teens Drops, But Persists Among Younger Children

In Brief

Dr. Reddy’s launches Allegra-D equivalent

FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action

Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel